Droia Ventures — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Hyku Biosciences develops covalent medicines to improve patient outcomes by advancing the scientific boundaries of this therapeutic approach.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Kleem Chaudhary, PhD(President & CEO)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)LAURA TADVALKAR(Director)
Board seatMatthias Van Woensel· per SEC Form D
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)Shafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)
Board seatLuc Dochez· per SEC Form D
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.